Phio Pharmaceuticals Corp. (PHIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 23, 2024, details a capital raise event for Phio Pharmaceuticals Corp. The company, incorporated in Delaware and trading on the Nasdaq Capital Market, entered into a securities purchase agreement to execute a concurrent Registered Direct Offering and Private Placement. The transaction closed on December 24, 2024.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 240,000 shares of Common Stock at $2.00 per share, accompanied by unregistered Series F Warrants to purchase up to 240,000 shares.
- Warrant Terms: Series F Warrants are immediately exercisable at $2.00 per share and expire five years from issuance. The purchase price for the warrants was included in the offering price per share.
- Net Proceeds: Approximately $0.48 million after deducting fees and expenses.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a 7.5% cash fee on gross proceeds, a 1.0% management fee, $10,000 for non-accountable expenses, $10,000 for clearing fees, and warrants to purchase 18,000 shares (Placement Agent Warrants) at an exercise price of $2.50.
Material Changes and Restrictions
The filing does not provide comparative financial data (revenue, profit, or cash flow) as this is a transaction-specific report rather than a periodic financial statement. However, the transaction introduces the following material changes and restrictions:
- Lock-Up Period: The Company is prohibited from issuing or announcing the issuance of Common Stock or equivalents from December 23, 2024, through January 8, 2025.
- Variable Rate Transaction Ban: Prohibited from entering into Variable Rate Transactions until December 23, 2025, with an exception allowing an at-the-market facility starting January 9, 2025.
- Registration Obligation: The Company must register the Warrant Shares for resale within 30 days and use commercially reasonable efforts to declare the registration statement effective within 60 days.
Outlook, Risks, and Contingencies
The filing outlines standard contingencies related to Fundamental Transactions (e.g., mergers or acquisitions). In such events, warrant holders are entitled to consideration equal to the Black-Scholes value of their warrants or the same choice of consideration as common stockholders. The filing incorporates by reference the full text of the Securities Purchase Agreement and warrant forms for complete terms.
Key Facts for Investor Verification
- Verify the exact net proceeds of $0.48 million against the gross proceeds of $0.48 million (240,000 shares x $2.00) to confirm the total deduction of fees and expenses.
- Confirm the dilution impact of the 240,000 new shares and the potential 240,000 additional shares from Series F Warrants, plus 18,000 shares from Placement Agent Warrants.
- Monitor the Company's compliance with the 30-day and 60-day registration deadlines for the Warrant Shares.
- Review the press release (Exhibit 99.1) for any additional commentary on the use of proceeds not detailed in the 8-K text.